T2	condition 370 406	anthracycline-induced cardiotoxicity
T3	No-of-participants 487 493	Eighty
T4	eligibility 494 543	female, chemotherapy-na√Øve breast cancer patients
T5	average-age 556 558	49
T1	intervention 14 66	lecithinized human recombinant super oxide dismutase
T6	control 780 787	placebo
T7	outcome-Measure 887 919	rotection against cardiac damage
T8	outcome 1260 1320	NT-proBNP concentration and prolongation of the QTc interval
T9	outcome 1412 1450	systolic or diastolic cardiac function
